Clinical Trials | June 09, 2026
The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions
At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
New Chesterbrook office strengthens customer engagement, partner collaboration, and regional expansion strategy
The company has announced its entry into India’s rapidly expanding nutraceuticals and wellness sector with the launch of Neat Everyday, a new consumer wellness brand
First installation of AI-powered AMULET SOPHINITY at NM Medical aims to strengthen early breast cancer detection
The collaboration will foster joint research initiatives, scientific knowledge exchange, and innovation
Advanced molecular diagnostics solution enables rapid, high-accuracy biomarker detection for precision oncology
New-generation platform enhances anatomical visualization, streamlines surgical workflows, and expands access to advanced navigation technology for ENT surgeons across Europe
The newly constituted committee will facilitate timely brain stem death certification, supporting transparent organ donation processes and expanding opportunities for patients awaiting transplants
Subscribe To Our Newsletter & Stay Updated
